Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic triggers Wyeth, J&J suit

This article was originally published in Clinica

Executive Summary

Wyeth and Johnson & Johnson have reacted to the FDA approval of Medtronic's Endeavor drug-eluting stent (DES) by filing suit against the product. The companies allege that the Endeavor DES, which was approved in February (see Clinica No 1293, p 1), infringes on three patents owned by Wyeth and licensed to J&J. Wyeth's patents - numbers '781, '146 and '728 - relate to the use of rapamycin or sirolimus in stents for patients undergoing angioplasty and vascular disease procedures. Medtronic's DES uses zotarolimus, an analogue of rapamycin and sirolimus. The lawsuit has asked the District Court of New Jersey to block Medtronic from selling the Endeavor DES in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel